Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis
New England Journal of Medicine · 30.01.2025 · 392 (5) · 468-482
DOI: 10.1056/nejmoa2400327 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 30.01.2025. Verfasst von Lorenzo Guglielmetti und 41 weiteren Autor:innen. Beteiligte Einrichtung: From Médecins Sans Frontières (L.G., F.V.), Sorbonne Université, INSERM Unité 1135, Centre d'Immunologie et des Maladies Infectieuses (L.G.), Assista…. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, NIAID NIH HHS, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Médecins Sans Frontières (L.G., F.V.), Sorbonne Université, INSERM Unité 1135, Centre d'Immunologie et des Maladies Infectieuses (L.G.), Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Universitaire Sorbo…
ORCID-Profile: Gustavo E Velásquez, Elisabeth Baudin, Catherine Berry, Ilaria Motta, Payam Nahid, Kwonjune J Seung, Carole D Mitnick
Förderung
- Wellcome Trust
- NIAID NIH HHS
- Fonds Wetenschappelijk Onderzoek
- Unitaid
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Guglielmetti, L., Khan, U., Velásquez, G. E., Gouillou, M., Abubakirov, A., Baudin, E., Berikova, E., Berry, C., Bonnet, M., Cellamare, M., Chavan, V., Cox, V., Dakenova, Z., de Jong, B. C., Ferlazzo, G., Karabayev, A., Kirakosyan, O., Kiria, N., Kunda, M., …, & endTB Clinical Trial Team (2025). Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. New England Journal of Medicine, 392(5), 468-482. https://doi.org/10.1056/nejmoa2400327
Vancouver
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. New England Journal of Medicine. 2025;392(5):468-482. doi:10.1056/nejmoa2400327
BibTeX
@article{Guglielmetti2025,
author = {Guglielmetti, Lorenzo and Khan, Uzma and Velásquez, Gustavo E and Gouillou, Maelenn and Abubakirov, Amanzhan and Baudin, Elisabeth and Berikova, Elmira and Berry, Catherine and Bonnet, Maryline and Cellamare, Matteo and Chavan, Vijay and Cox, Vivian and Dakenova, Zhanna and de Jong, Bouke Catherine and Ferlazzo, Gabriella and Karabayev, Aydarkhan and Kirakosyan, Ohanna and Kiria, Nana and Kunda, Mikanda and Lachenal, Nathalie and Lecca, Leonid and McIlleron, Helen and Motta, Ilaria and Toscano, Sergio Mucching and Mushtaque, Hebah and Nahid, Payam and Oyewusi, Lawrence and Panda, Samiran and Patil, Sandip and Phillips, Patrick P J and Ruiz, Jimena and Salahuddin, Naseem and Garavito, Epifanio Sanchez and Seung, Kwonjune J and Ticona, Eduardo and Trippa, Lorenzo and Vasquez, Dante E Vargas and Wasserman, Sean and Rich, Michael L and Varaine, Francis and Mitnick, Carole D and endTB Clinical Trial Team, endTB Clinical Trial Team},
title = {Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {5},
pages = {468--482},
doi = {10.1056/nejmoa2400327}
}
EUVIMED